Navigation Links
Graffinity Enters into Drug Discovery Research Collaboration with Genentech
Date:10/15/2009

Heidelberg, Germany, October 15, 2009 / b3c newswire / - Graffinity Pharmaceuticals GmbH announced today that it has entered into a drug discovery research collaboration with Genentech, Inc, a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY). With this collaboration Genentech will gain access to Graffinitys proprietary, fragment-based drug discovery technology.

Under the terms of the agreement, Graffinity will receive technology access fees and optional payments for follow-up chemistry for the generation of novel, small molecule hits against a number of drug targets. Financial details of the transaction were not disclosed.

Mathias Woker, Chief Business Officer of Graffinity, stated, We are very pleased that Genentech has decided to partner with us in fragment-based drug discovery. This marks our second collaboration with Genentech, and we think that this new agreement demonstrates how attractive Graffinitys very large fragment library and rapid surface plasmon resonance (SPR) screening technology are.

Kristina Schmidt, CEO of Graffinity, remarked, Our label-free, biophysics-based screening technology has shown to be an important element for companies which choose to work with us. With the help of this technology we enable partners, such as Genentech, to explore drug targets that would remain white spaces on the map of drug discovery, if researchers were limited to other conventional high-throughput screening techniques.


About Graffinity Pharmaceuticals GmbH - www.graffinity.com

Heidelberg, Germany based Graffinity Pharmaceuticals is a leader in the field of small molecule fragment based drug discovery. The company pursues high-profile drug discovery collaborations with leading pharmaceutical and biotechnology companies worldwide. Graffinity employs a flexible business model which allows it to tailor programs to the specific needs of each partner and offers numerous benefits to its customers on a straightforward fee-for-service basis. Graffinitys fragment screening platform combines chemical microarrays with a proprietary method for the standardized, label-free detection of compound-protein interactions via SPR imaging. The companys rapid and scalable drug discovery technology explores a rich chemical universe to identify drug fragments which address challenging drug targets. With its 110,000-compound library that contains 23,000 true fragments, Graffinity possesses one of the most diverse fragment libraries. During the past three years Graffinity has established collaborations with pharmaceutical and biotechnology partners including Amgen, AstraZeneca, Boehringer-Ingelheim, Elan, Pfizer and Rigel.
Graffinitys unique fragment based discovery platform was invented in 1998, and has been in routine industrial use since 2002 in screening more than 85 drug targets.

Graffinity Media Contact for Europe:

Dr. Kristina Schmidt
CEO
Graffinity Pharmaceuticals GmbH
Tel. +49 6221 6510-112
kristina.schmidt@graffinity.com

Graffinity Media Contact for the Americas and Asia:

Mathias Woker
CBO
Graffinity Pharmaceuticals GmbH
Tel. +1 (401) 301-1086
mathias.woker@graffinity.com


'/>"/>
b3c newswire

Related biology news :

1. NIH expands Human Microbiome Project; funds sequencing centers and disease projects
2. BIO-key(R) Enters Strategic Partnership With Nlets
3. BIO-key(R) Enters Strategic Partnership With Nlets
4. The first DFG research centers to be funded for another four years
5. Tellme Enters Automotive Market
6. From sheet metal elements to host cells: DFG launches 10 new collaborative research centers
7. Sicilian word enters British genetic language
8. NSF and EPA establish 2 centers for environmental implications of nanotechnology
9. Zebra Technologies Enters Into Revolving Credit Agreement to Support Company Growth
10. Weight Watchers vs. fitness centers
11. AMBER Alert Safety Centers to Provide Child Safety Precautions at the New Jersey State Fair at the Meadowlands
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/13/2017)... SANTA MONICA, Calif. , April 13, 2017 /PRNewswire/ ... New York will feature emerging and ... Innovation Summits. Both Innovation Summits will run alongside the ... variety of speaker sessions, panels and demonstrations focused on ... east coast,s largest advanced design and manufacturing event will ...
(Date:4/11/2017)... Research and Markets has announced the addition of the ... ... grow at a CAGR of 30.37% during the period 2017-2021. ... prepared based on an in-depth market analysis with inputs from industry ... over the coming years. The report also includes a discussion of ...
(Date:4/6/2017)... Forecasts by Product Type (EAC), Biometrics, Card-Based ... & Logistics, Government & Public Sector, Utilities / Energy ... Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality & ... for a definitive report on the $27.9bn Access Control ... ...
Breaking Biology News(10 mins):
(Date:4/27/2017)... Orleans, La. (PRWEB) , ... ... ... Monitoring Technologies today announced a comprehensive rebrand and a name change to ... for the industrial and laboratory monitoring of polymer and biopharmaceutical manufacturing processes ...
(Date:4/27/2017)... 2017  Pendant Biosciences, Inc. (formerly Nanoferix, Inc.), a ... drug delivery technologies, today announced that it has been ... Toronto . Shawn Glinter ... noted, "We are excited to become part of the ... are honored to be the first Tennessee ...
(Date:4/26/2017)... ... 26, 2017 , ... WonderWorks, Myrtle Beach’s science focused amusement ... of deep space exploration and inspire space enthusiasts. The exhibit features interactive exhibits ... guest appearance by former Shuttle Astronaut Don Thomas. , The intergalactic weekend kicks ...
(Date:4/26/2017)... Baltimore, Maryland (PRWEB) , ... April 26, 2017 ... ... it will be demonstrating its new Bioflash MailGuardtm mail security screening solution at ... The Bioflash MailGuard system provides a fast, highly accurate, easy to ...
Breaking Biology Technology: